About: Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $310.12 (-0.23%)
KRYS NASDAQ Krystal Biotech Inc
Krystal Biotech Inc share price
KRYS price activity
Last Price
$310.120
Change (24hr)
-0.73 USD (0.23%)
Volume
43.27K
Volume (4w avg)
-
Open
$310.22
Day Range
$305.76 - $314.24
Previous Close
$310.84
Last Trade
05 Nov, 3:51 pm GMT+0
Delayed
05 Nov, 3:51 pm GMT+0
KRYS price performance
Delayed
05 Nov, 3:51 pm GMT+0
KRYS details
KRYS Market Signals